Veterinary Research Forum
Vet Res Forum

Production of recombinant goose parvovirus origin VP2 protein based on baculovirus expression system

Document Type : Original Article

Authors

Remziye Özbek 1
Mustafa Ozan Atasoy 1
Turhan Turan 1
Hakan Işıdan 1
Hasan Abaylı 2
Kezban Şahna 2

1 Department of Virology, Faculty of Veterinary Medicine, Sivas Cumhuriyet University, Sivas, Türkiye

2 Department of Virology, Faculty of Veterinary Medicine, Firat University, Elazığ, Türkiye

https://doi.org/10.30466/vrf.2025.2048354.4583
Abstract
Goose parvovirus causes major economic losses in the waterfowl industry due to the high mortality. Therefore, it is essential to establish protection/control objectives in the fight against the disease. The genome of goose parvovirus consists of three structural proteins, including VP1, VP2, and VP3. The VP2 is a candidate antigen in developing vaccines and diagnostic kits. This study aimed to produce the VP2 protein from a local goose parvovirus strain that causes serious infections in geese in Türkiye using the baculovirus expression vector system. To achieve this, the VP2 gene was first amplified by polymerase chain reaction, followed by purification and insertion into the pENTR™/TEV/D-TOPO™ entry vector. Then, the target gene in the pENTR™/TEV/D-TOPO™ vector was transferred to linear N-Term BaculoDirect™ DNA through LR recombination (site-specific recombination between attL and attR sites). The construct was transfected into Spodoptera frugiperda cells. To verify the production of baculoviral virions, a band of approximately 600 bp in length was obtained as a result of polymerase chain reaction amplification using external primer sets for both the VP2 gene and expression vector. The obtained band was purified and sequenced for confirmation. In addition, to confirm the production of the recombinant protein, western blot analysis was conducted utilizing the V5 epitope located at the N-terminus of the expressed protein, resulting in the detection of a ~65.00 kDa band corresponding to the VP2 gene. To detect protein expression in S. frugiperda cells infected with the recombinant baculovirus, immunofluorescence analysis was performed using the same epitope. 

Keywords

Baculovirus
Expression
Goose parvovirus
Recombinant protein
VP2

Subjects

1.     Huo X, Chen Y, Zhu J, et al. Evolution, genetic re-combination, and phylogeography of goose parvovirus. Comp Immunol Microbiol Infect Dis 2023; 102: 102079. doi: 10.1016/j.cimid.2023.102079.
2.     Wang J, Duan J, Meng X, et al. Cloning of the genome of a goose parvovirus vaccine strain SYG61v and rescue of infectious virions from recombinant plasmid in embryonated goose eggs. J Virol Methods 2014; 200: 41-46.
3.     Zadori Z, Erdei J, Nagy J, et al. Characteristics of the genome of goose parvovirus. Avian Pathol 1994; 23(2): 359-364.
4.     Tarasiuk K, Holec-Gąsior L, Ferra B, et al. The development of an indirect ELISA for the detection of goose parvovirus antibodies using specific VP3 subunits as the coating antigen. BMC Vet Res 2019; 15(1): 274. doi: 10.1186/s12917-019-2027-1.
5.     Tu M, Liu P, Liu F, et al. Construction of expression vectors of capsid proteins from goose parvovirus and investigation of the immunogenicity. Acta Virol 2018; 62(4): 415-423.
6.     Felberbaum RS. The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J 2015; 10(5): 702-714.
7.     Hong Q, Liu J, Wei Y, et al. Application of baculovirus expression vector system (BEVS) in vaccine development. Vaccines (Basel) 2023; 11(7): 1218. doi: 10.3390/vaccines11071218.
8.     Tsai CH, Chuang YC, Lu YH, et al. Carbohydrate metabolism is a determinant for the host specificity of baculovirus infections. iScience 2021; 25(1): 103648. doi: 10.1016/j.isci.2021.103648.
9.     Liu F, Wu X, Li L, et al. Use of baculovirus expression system for generation of virus-like particles: successes and challenges, Protein Expr Purif 2013; 90 (2): 104-116.
10. Fath-Goodin A, Kroemer J, Martin S, et al. Polydnavirus genes that enhance the baculovirus expression vector system. Adv Virus Res 2006; 68: 75-90.
11. Adeniyi AA, Lua LH. Protein expression in the baculovirus-insect cell expression system. In: Gerrard J, Domigan L (Eds). Protein nanotechnology: methods in molecular biology. 1st ed. New York, USA: Humana Press 2020; 17-37.
12. Isidan H, Turan T, Atasoy MO, et al. Molecular analysis of goose parvovirus field strains from a Derzsy’s disease outbreak reveals local European-associated variants. Arch Virol 2021; 166(7): 1931-1942.
13. Kardoğan Ö, Müştak HK, Müştak İB. The first detection and characterization of goose parvovirus (GPV) in Turkey. Trop Anim Health Prod 2020; 53(1): 36. doi: 10.1007/s11250-020-02463-8.
14. Bulut O, Dik I, Aslım HP, et al. Molecular characterization of goose parvovirus in geese of Turkey. Pesq Vet Bras 2021; 41: 3. doi: 10.1590/1678-5150-pvb-6903.
15. Kearse M, Moir R, Wilson A, et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012; 28(12): 1647-1649.
16. Wheatley SP, Wang YL. Indirect immunofluorescence microscopy in cultured cells. Methods Cell Biol 1998; 57: 313-332.
17. Yan YQ, Jin LB, Wang Y, et al. Goose parvovirus and the protein NS1 induce apoptosis through the AIF-mitochondrial pathway in goose embryo fibroblasts. Res Vet Sci 2021; 137: 68-76.
18. Ju H, Wei N, Wang Q, et al. Goose parvovirus structural proteins expressed by recombinant baculoviruses self-assemble into virus-like particles with strong immunogenicity in goose. Biochem Biophys Res Commun 2011; 409(1): 131-136.
19. Lee JW, Lin YM, Liu CH, et al. Passive and protective immunity in ducklings elicited by a parvovirus subunit vaccine with CpG adjuvant. Taiwan Vet J 2016; 42(2): 75-80.
20. Shang Y, Ma Y, Tang S, et al. Virus-like particles based on the novel goose parvovirus (NGPV) VP2 protein protect ducks against NGPV challenge. Vaccines (Basel) 2023; 11(12): 1768. doi: 10.3390/ vaccines11121768.
21. Zhang Q, Sun Y, Sun Y, et al. Expression of VP2 protein of novel goose parvovirus in baculovirus and evaluation of its immune effect. Microb Pathog 2024; 195: 106751. doi: 10.1016/j.micpath.2024.106751.
22. Duan Z, Xu H, Ji X, et al. Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases. Future Microbiol 2015; 10(8): 1307-1323.
23. Fan JH, Zuo YZ, Yang Z, et al. The development of an indirect ELISA for the detection of antibodies to goose parvovirus in blood serum. Lett Appl Microbiol 2013; 57(1): 26-32.
24. Liu YY, Yang WT, Shi SH, et al. Immunogenicity of recombinant Lactobacillus plantarum NC8 expressing goose parvovirus VP2 gene in BALB/c mice. J Vet Sci 2017; 18(2): 159-167.
25. Murphy CI, Piwnica-Worms H. Overview of the baculovirus expression system. Curr Protoc Neurosci 2000; Chapter 4: Unit 4.18. doi: 10.1002/0471142301. ns0418s10.
26. Le Gall-Reculé G, Jestin V, Chagnaud P, et al. Expression of muscovy duck parvovirus capsid proteins (VP2 and VP3) in a baculovirus expression system and demonstration of immunity induced by the recombinant proteins. J Gen Virol 1996; 77(Pt 9): 2159-2163.
27. Chen Z, Li C, Zhu Y, et al. Immunogenicity of virus-like particles containing modified goose parvovirus VP2 protein. Virus Res 2012; 169(1): 306-309.
28. Masoomi Dezfooli S, Tan WS, Tey BT, et al. Expression and purification of the matrix protein of Nipah virus in baculovirus insect cell system. Biotechnol Prog 2016; 32(1): 171-177.
29. Brown CS, Van Lent JW, Vlak JM, et al. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J Virol 1991; 65(5): 2702-2706.
30. Maranga L, Brazão TF, Carrondo MJ. Virus-like particle production at low multiplicities of infection with the baculovirus insect cell system. Biotechnol Bioeng 2003; 84(2): 245-253.
31. Antonis AF, Bruschke CJ, Rueda P, et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 2006; 24(26): 5481-5490.
32. Cecchini S, Negrete A, Virag T, et al. Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States. Clin Vaccine Immunol 2009; 16(5): 597-604.
33. Elia G, Desario C, Pezzoni G, et al. Recombinant ELISA using baculovirus-expressed VP2 for detection of antibodies against canine parvovirus. J Virol Methods 2012; 184(1-2): 98-102.
34. Jin H, Xia X, Liu B, et al. High-yield production of canine parvovirus virus-like particles in a baculovirus expression system. Arch Virol 2016; 161(3): 705-710.
35. Hashemzadeh MS, Gharari N. Biosynthesis of a VLP-type nanocarrier specific to cancer cells using the BEVS expression system for targeted drug delivery. J Genet Eng Biotechnol 2023; 21(1): 20. doi: 10.1186/s43141-023-00479-9.
36. Jiao C, Zhang H, Liu W, et al. Construction and immunogenicity of virus-like particles of feline parvovirus from the tiger. Viruses 2020; 12(3): 315. doi: 10.3390/v12030315.
37. Wubshet AK, Li GX, Li Q, et al. Stability and integrity of self-assembled bovine parvovirus virus‑like particles (BPV‑VLPs) of VP2 and combination of VP1VP2 assisted by baculovirus-insect cell expression: a potential logistical platform for vaccine deployment. Virol J 2024; 21(1): 87. doi: 10.1186/s12985-024-02322-0.
38. Wang Q, Ju H, Li Y, et al. Development and evaluation of a competitive ELISA using a monoclonal antibody for antibody detection after goose parvovirus virus-like particles (VLPs) and vaccine immunization in goose sera. J Virol Methods 2014; 209: 69-75.
Veterinary Research Forum
Volume 17, Issue 1
January 2026
Pages 31-37

  • Receive Date 18 December 2024
  • Revise Date 06 March 2025
  • Accept Date 22 April 2025

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us